Sponsors

Lead Sponsor

AdventHealth Translational Research Institute

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Males and females ≥18 years of age.
•2. Able to read and speak English fluently.
•3. Reported ability to complete 20-30 minutes moderate exercise per positive response to, "Can you currently walk unaided for six minutes or more?"
•4. Scheduled for first-time checkpoint blockade immunotherapy with avelumab, cemiplimab, ipilimumab, nivolumab, or pembrolizumab in the absence of other therapies (e.g. targeted therapy) with the following diagnosis:
•1. Adjuvant setting: cutaneous melanoma.
•2. Neoadjuvant setting: cutaneous melanoma, cuSCC, or Merkel cell carcinoma.
•5. States willingness to follow protocol as described, including the prescribed exercise level and completing any forms needed throughout the study.
•6. Voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.

Exclusion Criteria

•7. Presence of medical conditions, such as severe cardiovascular disease for which exercise may be contraindicated. Participants may be referred to their medical team to obtain a cardiology approval.
•8. Presence of major postoperative complications for which an exercise intervention may be contraindicated.
•9. Currently has a chronic, contagious, infectious disease, such as active tuberculosis, active Hepatitis B or C, HIV, or COVID-19, per self-report.
•10. Currently pregnant, lactating or planning to become pregnant (positive result on urine pregnancy testing).
•11. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.

Related studies

RECRUITINGPhase 2

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279 · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, and more

RECRUITINGPhase 1/2

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

NCT05588453 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, and more

RECRUITINGPhase 1

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

NCT04855435 · Advanced Solid Tumor, Uveal Melanoma, Metastatic, and more

RECRUITINGPhase 1

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

NCT05076760 · Solid Tumor, Advanced Cancer, and more

RECRUITINGPhase 1

A Study of CRD3874-SI in People With Solid Tumors

NCT06021626 · Sarcoma, Merkel Cell Carcinoma

View all related studies →

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

A Study of CRD3874-SI in People With Solid Tumors

Trial snapshot

Condition

Locations shown

For caregivers